Childrens Giltuss Ex Expectorant Solution
NDC Package 65852-016-04
Package Information
Childrens Giltuss Ex Expectorant (guaifenesin) solution is directionsDo not take more than 6 doses in any 24 hours perioduse enclosed dosing cupKeep dosage cup for use with this productml= mililiterschildren under 4 years of age Consult a doctorchildren 4 to under 6 years of age 2.5 ml every 4 hourschildren 6 to under 12 years of age 5 ml every 4 hoursAdults and children 12 years & over 10 ml every 4 hours. This formulation utilizes a solution delivery system. Marketed by Dextrum Laboratories Inc., this product is identified by NDC 65852-016 and is authorized under FDA application M012.
Identification & Billing
- RxCUI: 310625 - guaiFENesin 200 MG in 5 mL Oral Solution
- RxCUI: 310625 - guaifenesin 40 MG/ML Oral Solution
- RxCUI: 310625 - guaifenesin 200 MG per 5 ML Oral Solution
- RxCUI: 310625 - guaifenesin 400 MG per 10 ML Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 65852 - Dextrum Laboratories Inc.
- 65852-016 - Childrens Giltuss Ex Expectorant
- 65852-016-04 - 1 BOTTLE, PLASTIC in 1 CARTON / 118 mL in 1 BOTTLE, PLASTIC
- 65852-016 - Childrens Giltuss Ex Expectorant
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 65852-016-04 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 118 ml in 1 bottle, plastic of Childrens Giltuss Ex Expectorant, a human over the counter drug labeled by Dextrum Laboratories Inc.. This solution is formulated for oral use and contains guaifenesin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Dextrum Laboratories Inc. on June 22, 2020. The current certification is valid through December 31, 2026.
How is this Dextrum Laboratories Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 65852001604. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.